Onco Actu du 27 février 2018

	1. Biologie
Breast cancer’s spread routes mapped [Karolinska Institutet] In the new study, the researchers have looked at the DNA in cancer tissue from 20 patients with breast tumours and metastases in both their axillary lymph nodes and other organs.
	2.11 Etiologie - Alimentation
Sugar-sweetened soft drinks and cancer: What you need to know [HealthNewsReview] Second, just how much sugary soft drinks subjects consumed was based on self-report in questionnaires. The authors clearly state this is “the main weakness or our study … self-report may not be accurate” and is nearly impossible to validate. This major limitation was not included in any of the reporting I reviewed.
	3.2 Prévention - Obésité
Millennials top obesity chart before reaching middle age [Cancer Resarch UK] More than seven in 10 millennials – those born between the early 80s and mid 90s – are set to be overweight or obese between the ages of 35-44, according to estimates by Cancer Research UK. This compares to around five in 10 baby boomers – those born between 1945-55 – who were overweight or obese at the same age.
Does losing weight reduce the risk of cancer? [Cancer Research UK] Overall, all the research carried out so far suggests that an increased risk can start to fall with weight loss.
	4.5 Dép., diag. & prono. - Colorectal
Exact Sciences: Severe Flu Season Slows Down Cancer Test’s Sales [Xconomy] “We recently conducted a survey of 600 primary care physicians,” Elliott said Thursday. “Those physicians had canceled 21 percent of wellness visits over the last two months due to the flu outbreak and extreme winter weather. Many physicians are delaying preventative care while they deal with the flu.”
	5.12.1 Immunothérapies - partenariats
Yale Cancer Center joins BMS’ II-ON immuno-oncology network [FierceBiotech] BMS is looking to the network to help bring forward a new generation of I-O drugs behind the current products, which include its PD-1 inhibitor Opdivo (nivolumab) and CTLA4 blocker Yervoy (ipilimumab).
Bristol-Myers Squibb Announces Expansion of the International Immuno-Oncology Network (II-ON) with Addition of Yale Cancer Center [BMS] Global collaboration founded by Bristol-Myers Squibb in 2012 now includes 16 leading academic institutions.
	5.12.2 Immunothérapies - CAR-T
CAR-T cell therapy: 9 things to know [MD Anderson Cancer Center] Clinical trials have a limited number of slots available, and there can be a long waiting list. So, patients should ask their doctors early on about clinical trial options when they are considering treatment for their cancer.
	5.12.5 Immunothérapies - Pharma
Johns Hopkins spinout spotlights a showcase animal test for antibody-ligand I/O traps — matching checkpoints with a rein on Tregs [EndPoints] The research team under Bedi created a Y-trap: fusing a CTLA-4 antibody as well as a PD-1 with a “TGFβ trap” designed to turn off, redirect and delete Tregs.
	5.3 Traitements - FDA, EMA, NICE...
Tissue Agnostic Therapies in Oncology: Regulatory Considerations for Orphan Drug Designation; Public Workshop; Request for Comments [Federal Register] The purpose of the public workshop is to discuss factors FDA should consider when evaluating drugs for orphan designation that treat a tissue agnostic disease or condition in oncology, and additional factors related to orphan exclusivity FDA should consider when approving a product with a tissue agnostic indication.
Towards more ethical use of animals in medicine testing [EMA] First report on EMA’s actions to replace, reduce, refine use of animals in medical research.
	5.3.4 Traitements - AMM (FDA, EMA,...)
Lilly Receives Additional FDA Approval for Verzenio™ (abemaciclib), as Initial Treatment for Advanced Breast Cancer [Lilly] Verzenio is the only CDK4 & 6 inhibitor approved across HR+, HER2- metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant and as a single agent, and is the only CDK4 & 6 inhibitor approved with a continuous dosing schedule.
EMA Recommends Refusal of the Marketing Authorisation for Neratinib [ESMO] It was intended for the treatment of patients with HER2-positive early breast cancer who had already received trastuzumab, but who were at high risk of cancer recurrence.
EMA Adopts a Negative Opinion for Extension of Indications for Sunitinib [ESMO] It was expected to use sunitinib to delay or prevent the recurrence of renal cell carcinoma in patients who have had surgery and are at high risk for relapse.
Lilly breast cancer drug wins expanded U.S. approval [Reuters] Verzenio was originally approved last September in combination with AstraZeneca’s Faslodex (fulvestrant) once the disease had progressed following endocrine therapy. The Lilly oral drug competes with Pfizer’s Ibrance and Kisqali from Novartis.
FDA approves abemaciclib as initial therapy for HR-positive, HER2-negative metastatic breast cancer [FDA] Approval was based on MONARCH 3, a randomized (2:1), double-blinded, placebo-controlled, multicenter clinical trial in postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer. A total of 493 patients were randomized to receive either abemaciclib 150 mg or placebo orally twice daily, plus physician’s choice of letrozole or anastrozole.
	6. Lutte contre les cancers
His six-month “listening tour” almost over, Sharpless discusses his vision for NCI [The Cancer Letter] There are things that we have to do, like the clinical trials endeavor. I alluded to this, that it works, but it needs some structural changes to make it work as well as everyone would like.
	6.1 Observation
New report exposes scale of postcode lottery in breast cancer diagnosis, treatment and care across England [Breast Cancer Now] "Demographic time-bomb" in breast cancer workforce impacting patient outcomes, as 13% consultant breast radiologist posts are vacant – with pressures hitting North East in particular.
'Alarming' failings in cancer care fuel premature breast cancer deaths [The Telegraph] A report by the All-Party Parliamentary Group on Breast Cancer reveals a “postcode lottery” in screening, diagnosis and death rates from the disease.
	6.11 Patients
Many women fear and misunderstand breast cancer radiation [Reuters] While most women said they initially didn’t know much about radiation, roughly half had heard frightening stories, the survey found. After radiation, however, 92 percent of patients said they wouldn’t have been as scared if they had known in advance what to expect.
	6.5 Médecines alternatives
NIH needs to raise the bar for funding alternative medicine research [STAT] The fact that the National Center for Complementary and Integrative Health was allowed to spend $130 million in fiscal year 2016 is an affront to the NIH-funded researchers (and aspirants) who are at the cutting edge of their disciplines but face increasing difficulty getting federal funding for studies that rank high on scientific merit.
	6.6 Publications
Researchers have finally created a tool to spot duplicated images across thousands of papers [Nature] Publishers would need to join forces to apply image-checking software across the literature.